GILD Stock Analysis
NMS · Healthcare · Drug Manufacturers - General
$149.43
-1.50 (-0.99%)
GILD Interactive Price Chart & Trading Signals
GILD Stock Snapshot — Valuation, Risk & Technical Signals
GILD Key Fundamentals, Analyst Targets & Company Profile
Key Financial Ratios
Marktkapitalisierung
$185.29B
P/E
—
Forward P/E
15.11
PEG
2.24
P/B
15.68
EPS
$-2.66
Dividendenrendite
2.17%
52W Spanne
$108.46 – $157.29
Beta
0.35
Volumen
0.1M
ROE
-20.7%
Gewinnmarge
-10.6%
Umsatzwachstum
10.2%
Bruttomarge
79.6%
EV/EBITDA
14.28
Analystenziel
$158.65
Forward P/E of 15.1x suggests earnings compression ahead. Price-to-book is 15.68x. EV/EBITDA sits at 14.28x. Market capitalization is $185.29B. Revenue is growing at 10.2% on a trailing basis. Beta of 0.35 indicates defensive profile.
Analyst Consensus
Empfehlung
Buy
Ziel niedrig
$123.00
Ziel Mittel
$158.65
Ziel hoch
$180.00
Basierend auf 26 Analysten
Über GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.
GILD Deep Dive Analysis
Bottom Line
Verdict
OvervaluedBest for
General investorWatch out for
Premium valuationNon-zero inputs
3/5Counts non-zero values for price, P/E, beta, macro risk, and revenue growth; zero may mean unavailable or be a genuine zero.
Gilead Sciences, Inc. (GILD) trades above our multi-model fair value estimate of $115.13 by approximately 23.0%. Recent growth metrics show revenue growth of 10.2%. Risk profile: defensive beta of 0.35. Consensus: buy.
Valuation, Growth & Risk
Valuation
Overvalued
Price is above what fundamentals suggest.
Growth
Expanding
Rev 10.2%
Revenue is outpacing the market.
Risk
Low
Beta 0.35
Movement is likely to track the broader market.
Valuation Snapshot
Gilead Sciences, Inc. (GILD) trades above our multi-model fair value estimate of $115.13 by approximately 23.0%. Forward P/E of 15.1x indicates stable forward expectations. Price-to-sales is 6.1x. Price-to-book is 15.7x. EV/EBITDA sits at 14.3x. Market capitalization is $185.29B.
Why it matters: Paying a premium works only if the company keeps growing faster than expected.
Growth & Profitability
Revenue is growing at 10.2% on a trailing basis. Return on assets is 14.1%.
Why it matters: Growing revenue with healthy margins usually means the business is gaining market share or pricing power.
Risk Profile
Beta of 0.35 indicates defensive profile. Net debt position is $21.36B.
Why it matters: Lower risk means steadier returns, but often with less upside in bull markets.
Analyst Context
Analyst consensus target of $158.65 implies 6.2% upside. Target range spans $123.00 to $180.00. 26 analysts cover the stock. Consensus recommendation: buy.
Why it matters: Analyst targets reflect what professionals expect over 12 months. A wide gap between price and target can mean the market disagrees with the consensus.
Investor Fit
Free cash flow yield of 5.1% is attractive for cash-flow-focused investors.
Takeaway: Match the stock's risk-reward profile with your own goals and time horizon. No single metric tells the whole story.
Data Methodology & Sources
Market Data (Facts)
- Price, volume, and market cap: Yahoo Finance (may be delayed)
- P/E, EPS, revenue, and debt: Yahoo Finance fundamentals
- Analyst estimates: Yahoo Finance (coverage and update times vary)
- Insider transactions: Yahoo Finance (reporting may be delayed)
QuantSoar Model (Derived)
- Fair value: available outputs from seven models; outliers are filtered using MAD (k=3.5), then combined with fixed model weights.
- Margin of Safety = (Fair Value − Displayed Price) / Displayed Price × 100
- Composite Score: 40% Value + 30% Momentum + 30% Risk
- Verdict Gauge: Base 50 + Valuation (up to ±25) + Whale sentiment (up to ±10) + Insider buying (+5) + Macro risk (up to ±10) + Technical signal (up to ±10). Analyst consensus is separate.
Model outputs are estimates based on available data and are not investment advice. Cross-check with primary sources before making investment decisions.
GILD Overvalued
Gilead Sciences, Inc. (GILD) trades above our multi-model fair value estimate of $115.13 by approximately 23.0%.
Frequently Asked Questions
ValuationIs GILD stock overvalued right now?
ValuationWhat is GILD fair value based on current fundamentals?
RiskHow risky is GILD compared with other stocks?
GrowthIs GILD still growing?
AnalystWhat do analysts think about GILD?
DividendDoes GILD pay a dividend?
CatalystWhat could change the investment case for GILD?
Related Stocks
เกี่ยวกับผู้เขียน
Phasakorn Traklang (Peach) — ผู้ก่อตั้ง
ภาสกร ตรากลาง (พีช) เป็นผู้ก่อตั้ง QuantSoar และนักวิจัยการลงทุนเชิงปริมาณที่เชี่ยวชาญด้านการประเมินมูลค่าหุ้นหลายโมเดล การวิเคราะห์กระแสสถาบัน และการสร้างพอร์ตแบบเป็นระบบ เขาสร้างแพลตฟอร์มการเงินที่ขับเคลื่อนด้วยข้อมูลเพื่อให้บริการนักลงทุนรายย่อยทั่วโลก
เชื่อมต่อ LinkedInInvestment Disclaimer: Tax treatment can depend on tax residence, account type, and tax year. This information is general and is not personal tax or investment advice. SEC
Daten: Yahoo Finance / SEC EDGAR / Alpha Vantage / Finnhub